Open Access
Methods for health economic evaluation
Craig R Ramsay,Robert Pickard,C Robertson,A Close,Luke Vale,Nigel Armstrong,DA Barocas,Christopher G. Eden,Christophe Fraser,Tara Gurung,D Jenkinson,X Jia,Thomas B Lam,Graham Mowatt,David E. Neal,Max Robinson,J Royle,Steve P. Rushton,Pawana Sharma,Mdf Shirley,Naeem Soomro +20 more
- 01 Nov 2012
10
About: The article was published on 01 Nov 2012. and is currently open access. The article focuses on the topics: Health informatics & Economic evaluation.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital
Sebastian M. Heimann,Jorg-Janne Vehreschild,Oliver A. Cornely,H. Wisplinghoff,Michael Hallek,R. Goldbrunner,Bernd W. Böttiger,T. Goeser,A. Hölscher,Stephan Baldus,F. Müller,Nathalie Jazmati,S. Wingen,Bernd Franke,Maria J G T Vehreschild +14 more
TL;DR: Especially CDAD recurrence was associated with excessive costs, which were mostly attributable to a significantly longer overall length of stay and Innovative treatment strategies are warranted to reduce treatment costs and prevent recurrence of CDAD.
47
Korean guidelines for pharmacoeconomic evaluation (second and updated version) : consensus and compromise.
TL;DR: The revised guidelines clarify the expression of the recommendations, making them more user-friendly, and provide more specific guidance to improve the quality and comparability across submissions.
42
Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole
Sebastian M. Heimann,Oliver A. Cornely,H. Wisplinghoff,Matthias Kochanek,Dirk L. Stippel,S. A. Padosch,G Langebartels,H. Reuter,M. Reiner,A. Vierzig,Harald Seifert,Maria J G T Vehreschild,Jan Peter Glossmann,Bernd Franke,Jorg-Janne Vehreschild +14 more
TL;DR: Sicker patients had a prolonged hospitalization and were more likely to receive echinocandins, leading to higher treatment costs, and the health economic analysis shows the high treatment costs of patients with candidemia in the ICU.
35
Defining innovation with respect to new medicines: a systematic review from a payer perspective.
Oriol Sola-Morales,David Cunningham,Mathias Flume,Paul M Overton,Natalie Shalet,Stefano Capri +5 more
TL;DR: Alignment across countries and among regulators, health technology assessment bodies and payers would help manufacturers define research policies that can drive innovation, but may be challenging, as judgements about what aspects of innovation should be rewarded vary among stakeholders, and depend on political and societal factors.
16
Good Days and Bad Days: Measuring Health-Related Quality of Life in People With Epilepsy.
Valérie Wester,Saskia de Groot,Matthijs Versteegh,Tim A. Kanters,Louis Wagner,Jacqueline Ardesch,Werner B. F. Brouwer,Job van Exel,Marie-José Enders-Slegers,M. de Ruiter,I. Corro-Ramos,S. le Cessie,J. Mourits,J. van den Hurk-van Schadewijk,U. de Wit,H. Marell,H. Verhoeven +16 more
TL;DR: When HRQoL is measured at regular time intervals, PWE seem more likely to complete these surveys on good days, which could lead to underestimation of the effectiveness of treatment and to biased estimates of cost-effectiveness.
3